Cooper Companies

COO Health Care Market cap $10.6B as of Sep 14, 2026 16:00 ET S&P 500

Q3 FY26 May 1 – Jul 31, 2026 reported Sep 9, 2026

Revenue$1.07B +1% year over year

Gross profit$0.71B 67% margin

Operating profit$0.22B 21% margin

Net profit$0.43B 41% margin

Net profit is larger than what operations earned, because the statement adds $0.23B below it, under Tax benefit.

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q3 FY26 (period ends Jul 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.07	100%	+1%
CooperVision	0.72	67%
CooperSurgical	0.35	33%
Cost of revenue	−0.35	33%
Gross profit	0.71	67% margin	+2pp
R&D	−0.04	4%	+0pp
SG&A	−0.40	38%	−2pp
Other	−0.05	4%	+0pp
Operating profit	0.22	21% margin	+4pp
Interest & other costs	−0.02
Tax benefit	0.23
Net profit	0.43	41% margin	+31pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Apr 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.08	100%	+8%
CooperVision	0.72	67%
CooperSurgical	0.36	33%
Cost of revenue	−0.35	32%
Gross profit	0.74	68% margin	+0pp
R&D	−0.04	4%	−1pp
SG&A	−0.68	62%	+23pp
Other	−0.05	5%	+0pp
Operating profit	−0.03	−3% margin	−21pp
Interest & other costs	−0.02
Tax	−0.03
Net profit	−0.08	−7% margin	−16pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Jan 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.02	100%	+6%
CooperVision	0.70	68%
CooperSurgical	0.33	32%
Cost of revenue	−0.33	32%
Gross profit	0.70	68% margin	−1pp
R&D	−0.04	4%	+0pp
SG&A	−0.39	38%	−2pp
Other	−0.05	5%	+0pp
Operating profit	0.21	21% margin	+2pp
Interest & other costs	−0.02
Tax	−0.06
Net profit	0.13	13% margin	+2pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Oct 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.07	100%	+5%
Cost of revenue	−0.41	39%
Gross profit	0.65	61% margin	−5pp
R&D	−0.04	4%	+0pp
SG&A	−0.42	39%	+1pp
Other	−0.05	5%	+0pp
Operating profit	0.14	13% margin	−6pp
Interest & other costs	−0.02
Tax	−0.03
Net profit	0.09	8% margin	−4pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Jul 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.06	100%	+6%
Sphere, other	0.36	34%	+3%
Toric & multifocal	0.36	34%	+10%
Office & surgical	0.21	19%	+3%
Fertility	0.14	13%	+6%
Cost of revenue	−0.37	35%
Gross profit	0.69	65% margin	−1pp
R&D	−0.05	4%	+0pp
SG&A	−0.42	40%	+2pp
Other	−0.05	5%	+0pp
Operating profit	0.18	17% margin	−3pp
Interest & other costs	−0.02
Tax	−0.05
Net profit	0.10	9% margin	−1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Apr 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.00	100%	+6%
Sphere, other	0.34	34%
Toric & multifocal	0.33	33%
Office & surgical	0.21	20%
Fertility	0.13	13%
Cost of revenue	−0.32	32%
Gross profit	0.68	68% margin	+1pp
R&D	−0.05	4%	+0pp
SG&A	−0.40	40%	−1pp
Other	−0.05	5%	+0pp
Operating profit	0.19	18% margin	+1pp
Interest & other costs	−0.04
Tax	−0.06
Net profit	0.09	9% margin	−1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Jan 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	0.97	100%	+4%
United States	0.50	51%
Europe	0.29	30%
Rest of world	0.18	19%
Cost of revenue	−0.31	32%
Gross profit	0.66	68% margin	+1pp
R&D	−0.04	5%	+0pp
SG&A	−0.39	40%	−1pp
Other	−0.05	5%	+0pp
Operating profit	0.18	19% margin	+2pp
Interest & other costs	−0.03
Tax	−0.05
Net profit	0.10	11% margin	+2pp

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q3 FY26 May 1 – Jul 31, 2026 reported Sep 9, 2026 Operating margin 21% Net profit $0.43B	May 1 – Jul 31, 2026	Sep 9, 2026	$1.07B	+1%	21%	$0.43B	41%
Q2 FY26 Feb 1 – Apr 30, 2026 reported Jun 5, 2026 Operating margin −3% Net profit −$0.08B	Feb 1 – Apr 30, 2026	Jun 5, 2026	$1.08B	+8%	−3%	−$0.08B	−7%
Q1 FY26 Nov 1, 2025 – Jan 31, 2026 reported Mar 6, 2026 Operating margin 21% Net profit $0.13B	Nov 1, 2025 – Jan 31, 2026	Mar 6, 2026	$1.02B	+6%	21%	$0.13B	13%
Q4 FY25 Aug 1 – Oct 31, 2025 reported Dec 5, 2025 Operating margin 13% Net profit $0.09B	Aug 1 – Oct 31, 2025	Dec 5, 2025	$1.07B	+5%	13%	$0.09B	8%
Q3 FY25 May 1 – Jul 31, 2025 reported Aug 28, 2025 Operating margin 17% Net profit $0.10B	May 1 – Jul 31, 2025	Aug 28, 2025	$1.06B	+6%	17%	$0.10B	9%
Q2 FY25 Feb 1 – Apr 30, 2025 reported May 30, 2025 Operating margin 18% Net profit $0.09B	Feb 1 – Apr 30, 2025	May 30, 2025	$1.00B	+6%	18%	$0.09B	9%
Q1 FY25 Nov 1, 2024 – Jan 31, 2025 reported Mar 7, 2025 Operating margin 19% Net profit $0.10B	Nov 1, 2024 – Jan 31, 2025	Mar 7, 2025	$0.97B	+4%	19%	$0.10B	11%